Literature DB >> 1553789

Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing.

S M Grimmond1, D Raghavan, P J Russell.   

Abstract

This paper represents the first report of a codon 59 mutation in Ki-ras from a spontaneous human transitional cell carcinoma of the bladder. Point mutations have the potential to activate the ras genes if they occur in critical coding regions. These include the sequences of codons 12, 13, 59, 61 and 63. Mutations in codons 12, 13 and 61 have been reported in a wide variety of human cancers, including transitional cell carcinoma of the bladder. However mutations in codon 59 have been reported only in retroviral Ki-ras and as a result of in vitro mutagenesis experiments. We have used the polymerase chain reaction and direct sequencing to detect mutations of Ki-ras, and allele-specific restriction analysis to detect mutations of N-ras in xenografts and continuous cell lines established from bladder cancer biopsies of ten different patients as well as in direct biopsy specimens from five human bladder tumours. For studies of Ki-ras, a 139 bp fragment which spanned the critical codons 12 and 13 and a 128 bp fragment that spanned the sequences of codon 59, 61 and 63 were enzymatically amplified and then sequenced. No N-ras mutations were detected. A heterozygous mutation of Ki-ras at codon 59 GCA----G/ACA was detected in one line. This mutation is being expressed and appears stable as it was detected over several xenograft passages and was present in paraffin-embedded tissue from the primary tumour of the patient. The biological significance of the mutation in bladder cancer is currently under study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553789     DOI: 10.1007/bf00296523

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  28 in total

1.  Errors in the polymerase chain reaction.

Authors:  A M Dunning; P Talmud; S E Humphries
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

2.  All three human ras genes are expressed in a wide range of tissues.

Authors:  G Fiorucci; A Hall
Journal:  Biochim Biophys Acta       Date:  1988-05-06

3.  Polymorphic DNA region adjacent to the 5' end of the human insulin gene.

Authors:  G I Bell; J H Karam; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

4.  Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene.

Authors:  J P McGrath; D J Capon; D H Smith; E Y Chen; P H Seeburg; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1983 Aug 11-17       Impact factor: 49.962

5.  Point mutations in both transforming and non-transforming codons of the N-ras proto-oncogene of Ph+ leukemias.

Authors:  G Rovera; B A Reichard; S Hudson; S Bittenbender; M Yamada; O Tournay; H D Preisler
Journal:  Oncogene       Date:  1989-07       Impact factor: 9.867

6.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

7.  Bladder cancer xenografts: a model of tumor cell heterogeneity.

Authors:  P J Russell; D Raghavan; P Gregory; J Philips; E J Wills; M Jelbart; J Wass; R A Zbroja; P C Vincent
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

8.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Conformational alterations detected by circular dichroism induced in the normal ras p21 protein by activating point mutations at position 12, 59, or 61.

Authors:  A Valencia; L Serrano; R Caballero; P S Anderson; J C Lacal
Journal:  Eur J Biochem       Date:  1988-07-01

10.  Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction.

Authors:  D K Shibata; N Arnheim; W J Martin
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  4 in total

1.  Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.

Authors:  Emil Lou; Donna D'Souza; Andrew C Nelson
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

2.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; R Kucway; W Du; D S Kamarauskiene; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-04

3.  K-RAS mutation in transitional cell carcinoma of urinary bladder.

Authors:  S Ayan; G Gokce; H Kilicarslan; O Ozdemir; E Yildiz; E Y Gultekin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Genetics of Bladder Malignant Tumors in Childhood.

Authors:  Andrea Zangari; Johan Zaini; Caterina Gulìa
Journal:  Curr Genomics       Date:  2016-02       Impact factor: 2.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.